Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease

The development of pharmacological therapies for mitochondrial diseases is hampered by the lack of tissue‐level and circulating biomarkers reflecting effects of compounds on endothelial and mitochondrial function. This phase 0 study aimed to identify biomarkers differentiating between patients with mitochondrial disease and healthy volunteers (HVs). In this cross‐sectional case–control study, eight participants with mitochondrial disease and eight HVs matched on age, sex, and body mass index underwent study assessments consisting of blood collection for evaluation of plasma and serum biomarkers, mitochondrial function in peripheral blood mononuclear cells (PBMCs), and an array of imaging methods for assessment of (micro)circulation. Plasma biomarkers GDF‐15, IL‐6, NT‐proBNP, and cTNI were significantly elevated in patients compared to HVs, as were several clinical chemistry and hematology markers. No differences between groups were found for mitochondrial membrane potential, mitochondrial reactive oxygen production, oxygen consumption rate, or extracellular acidification rate in PBMCs. Imaging revealed significantly higher nicotinamide‐adenine‐dinucleotide‐hydrogen (NADH) content in skin as well as reduced passive leg movement‐induced hyperemia in patients. This study confirmed results of earlier studies regarding plasma biomarkers in mitochondrial disease and identified several imaging techniques that could detect functional differences at the tissue level between participants with mitochondrial disease and HVs. However, assays of mitochondrial function in PBMCs did not show differences between participants with mitochondrial disease and HVs, possibly reflecting compensatory mechanisms and heterogeneity in mutational load. In future clinical trials, using a mix of imaging and blood‐based biomarkers may be advisable, as well as combining these with an in vivo challenge to disturb homeostasis.

[1]  Yujie Zhou,et al.  Mitochondrial Dysfunction in Cardiovascular Diseases: Potential Targets for Treatment , 2022, Frontiers in Cell and Developmental Biology.

[2]  I. D. de Coo,et al.  Blood biomarkers for assessment of mitochondrial dysfunction: An expert review. , 2021, Mitochondrion.

[3]  Salvatore Dibartolo,et al.  Metabolic Changes in Peripheral Blood Mononuclear Cells Isolated From Patients With End Stage Renal Disease , 2021, Frontiers in Endocrinology.

[4]  Owen S. Skinner,et al.  Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity. , 2021, The Journal of clinical investigation.

[5]  Bruce D. Johnson,et al.  Measurement of muscle blood flow and O2 uptake via near-infrared spectroscopy using a novel occlusion protocol , 2021, Scientific reports.

[6]  G. Santulli,et al.  Arginine and Endothelial Function , 2020, Biomedicines.

[7]  F. Dehghani,et al.  The Effect of Resveratrol on Mitochondrial Function in Myoblasts of Patients with the Common m.3243A>G Mutation , 2020, Biomolecules.

[8]  R. Garten,et al.  Passive Leg movement in Chronic Obstructive Pulmonary Disease: Evidence of locomotor muscle vascular dysfunction. , 2020, Journal of applied physiology.

[9]  Anita Saraf,et al.  Mitochondrial dysfunction and oxidative stress in heart disease , 2019, Experimental & Molecular Medicine.

[10]  Shi-Yan Ng,et al.  Mitochondrial 3243A > G mutation confers pro-atherogenic and pro-inflammatory properties in MELAS iPS derived endothelial cells , 2019, Cell Death & Disease.

[11]  F. de Blay,et al.  Mitochondrial Function in Peripheral Blood Mononuclear Cells (PBMC) Is Enhanced, Together with Increased Reactive Oxygen Species, in Severe Asthmatic Patients in Exacerbation , 2019, Journal of clinical medicine.

[12]  D. Schubert,et al.  Mitochondrial dysfunction impairs human neuronal development and reduces neuronal network activity and synchronicity , 2019, bioRxiv.

[13]  X. Zhang,et al.  Mitochondrial DNA mutation m.3243A>G is associated with altered mitochondrial function in peripheral blood mononuclear cells, with heteroplasmy levels and with clinical phenotypes , 2019, Diabetic medicine : a journal of the British Diabetic Association.

[14]  W. Jia,et al.  De Novo Mutation of m.3243A>G together with m.16093T>C Associated with Atypical Clinical Features in a Pedigree with MIDD Syndrome , 2019, Journal of diabetes research.

[15]  J. Tao,et al.  Mitochondrial dysfunction-mediated decline in angiogenic capacity of endothelial progenitor cells is associated with capillary rarefaction in patients with hypertension via downregulation of CXCR4/JAK2/SIRT5 signaling , 2019, EBioMedicine.

[16]  R. Tian,et al.  Targeting NAD+ Metabolism as Interventions for Mitochondrial Disease , 2019, Scientific Reports.

[17]  D. Chang,et al.  Alterations of oxygen consumption and extracellular acidification rates by glutamine in PBMCs of SLE patients. , 2019, Mitochondrion.

[18]  D. Dardevet,et al.  Peripheral Blood Mononuclear Cell Metabolism Acutely Adapted to Postprandial Transition and Mainly Reflected Metabolic Adipose Tissue Adaptations to a High-Fat Diet in Minipigs , 2018, Nutrients.

[19]  Robert W. Taylor,et al.  mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease , 2018, EMBO molecular medicine.

[20]  Melissa A H Witman,et al.  Altered vascular function in chronic kidney disease: evidence from passive leg movement , 2018, Physiological reports.

[21]  W. Teeuwisse,et al.  Validation of a pharmacological model for mitochondrial dysfunction in healthy subjects using simvastatin: A randomized placebo‐controlled proof‐of‐pharmacology study , 2017, European journal of pharmacology.

[22]  Kevin K. McCully,et al.  In Vivo Assessment of Mitochondrial Dysfunction in Clinical Populations Using Near-Infrared Spectroscopy , 2017, Front. Physiol..

[23]  G. Cortopassi,et al.  Oxidative stress in inherited mitochondrial diseases. , 2015, Free radical biology & medicine.

[24]  Robert W. Taylor,et al.  Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease , 2015, Annals of neurology.

[25]  Marni J. Falk,et al.  Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society , 2014, Genetics in Medicine.

[26]  M. Tesařová,et al.  Noninvasive diagnostics of mitochondrial disorders in isolated lymphocytes with high resolution respirometry , 2014, BBA clinical.

[27]  K. Murayama,et al.  Efficacy of pyruvate therapy in patients with mitochondrial disease: a semi-quantitative clinical evaluation study. , 2014, Molecular genetics and metabolism.

[28]  J. Auwerx,et al.  Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3 , 2014, EMBO molecular medicine.

[29]  G. Comi,et al.  The m.3243A>G mitochondrial DNA mutation and related phenotypes. A matter of gender? , 2014, Journal of Neurology.

[30]  E. Tibiriçá,et al.  Impairment of systemic microvascular endothelial and smooth muscle function in individuals with early-onset coronary artery disease: studies with laser speckle contrast imaging , 2014, Coronary artery disease.

[31]  D. Kerr.  Review of Clinical Trials for Mitochondrial Disorders: 1997–2012 , 2013, Neurotherapeutics.

[32]  N. Chandel,et al.  Physiological roles of mitochondrial reactive oxygen species. , 2012, Molecular cell.

[33]  Kevin K McCully,et al.  Noninvasive evaluation of skeletal muscle mitochondrial capacity with near-infrared spectroscopy: correcting for blood volume changes. , 2012, Journal of applied physiology.

[34]  G. Paolisso,et al.  Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[35]  Lisa T. Emrick,et al.  Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. , 2012, Molecular genetics and metabolism.

[36]  R. Rodenburg,et al.  Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation , 2012, Journal of Inherited Metabolic Disease.

[37]  E. Bouskela,et al.  Sidestream dark field imaging: the evolution of real-time visualization of cutaneous microcirculation and its potential application in dermatology , 2011, Archives of Dermatological Research.

[38]  M. Roustit,et al.  Local Thermal Hyperemia as a Tool to Investigate Human Skin Microcirculation , 2010, Microcirculation.

[39]  S. Dimauro,et al.  Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS , 2009, American journal of medical genetics. Part A.

[40]  M. Duchen,et al.  Endothelial Mitochondria: Contributing to Vascular Function and Disease , 2007, Circulation research.

[41]  S. Dimauro,et al.  Measurement of ATP production in mitochondrial disorders , 2006, Journal of Inherited Metabolic Disease.

[42]  M. Burnier,et al.  Postischemic forearm skin reactive hyperemia is related to cardovascular risk factors in a healthy female population , 2002, Journal of hypertension.

[43]  E. Stroes,et al.  Characterization of immune cell, endothelial, and renal responses upon experimental human endotoxemia. , 2018, Journal of pharmacological and toxicological methods.

[44]  S. Dimauro,et al.  Mitochondrial diseases , 2016, Nature Reviews Disease Primers.

[45]  R. Haller,et al.  Increased capillaries in mitochondrial myopathy: implications for the regulation of oxygen delivery. , 2012, Brain : a journal of neurology.